- Home
- URGN vs WIA Comparison
URGN vs WIA Comparison
Compare URGN & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- WIA
- Stock Information
- Founded
- URGN 2004
- WIA 2003
- Country
- URGN United States
- WIA United States
- Employees
- URGN N/A
- WIA N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- WIA Trusts Except Educational Religious and Charitable
- Sector
- URGN Health Care
- WIA Finance
- Exchange
- URGN Nasdaq
- WIA Nasdaq
- Market Cap
- URGN 181.2M
- WIA 190.7M
- IPO Year
- URGN 2017
- WIA N/A
- Fundamental
- Price
- URGN $14.82
- WIA $8.33
- Analyst Decision
- URGN Strong Buy
- WIA
- Analyst Count
- URGN 9
- WIA 0
- Target Price
- URGN $26.81
- WIA N/A
- AVG Volume (30 Days)
- URGN 5.9M
- WIA 39.2K
- Earning Date
- URGN 08-12-2025
- WIA 01-01-0001
- Dividend Yield
- URGN N/A
- WIA 12.29%
- EPS Growth
- URGN N/A
- WIA N/A
- EPS
- URGN N/A
- WIA N/A
- Revenue
- URGN $91,871,000.00
- WIA N/A
- Revenue This Year
- URGN $36.65
- WIA N/A
- Revenue Next Year
- URGN $88.35
- WIA N/A
- P/E Ratio
- URGN N/A
- WIA N/A
- Revenue Growth
- URGN 8.98
- WIA N/A
- 52 Week Low
- URGN $3.42
- WIA $7.56
- 52 Week High
- URGN $18.15
- WIA $8.91
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- WIA 68.59
- Support Level
- URGN $6.92
- WIA $8.19
- Resistance Level
- URGN $15.22
- WIA $8.21
- Average True Range (ATR)
- URGN 1.57
- WIA 0.06
- MACD
- URGN 1.17
- WIA 0.02
- Stochastic Oscillator
- URGN 96.49
- WIA 100.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.